Clinical Trials Browser

Phase 2 × durvalumab × Clear all

NCT04940286 2026-04-16

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05925530 2026-04-16

MDT-BRIDGE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Recruiting

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT04668300 2026-04-15

DOSa

Phase 2 Active not recruiting

Hemangiosarcoma, Liposarcoma, Osteosarcoma

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03446547 2026-04-14

ASTEROID

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT06667908 2026-04-14

CONVERGE

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06880523 2026-04-14

SLIDE-HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02888743 2026-04-13

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Phase 2 Active not recruiting

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03660826 2026-04-13

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Phase 2 Active not recruiting

288 enrolled 21 charts

Carcinosarcoma, Carcinoma, Endometrioid

NCT03907475 2026-04-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Phase 2 Recruiting

Neoplasm Metastasis

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT05198830 2026-04-13

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

Adenocarcinoma of Lung, Lung Neoplasms

NCT07339059 2026-04-09

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05034887 2026-04-08

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Gastric Adenocarcinoma

NCT06503614 2026-04-08

ENHANCE

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06728410 2026-04-08

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT05903092 2026-04-07

MOZART

Phase 2 Suspended

Small Cell Lung Carcinoma

NCT02087423 2026-04-06

ATLANTIC

Phase 2 Completed

446 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06050252 2026-04-03

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

Phase 2 Recruiting

Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

NCT03589547 2026-04-02

358

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03606967 2026-04-02

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT04245514 2026-04-02

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05733598 2026-04-02

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT03795207 2026-03-31

POSTCARD

Phase 2 Active not recruiting

Node; Prostate

NCT04607954 2026-03-31

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Phase 2 Active not recruiting

Platinum-Resistant Lung Small Cell Carcinoma

NCT06008093 2026-03-30

TRITON

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06769126 2026-03-30

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT04351256 2026-03-27

TRADE-hypo

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT05063565 2026-03-27

ROWAN

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT07036380 2026-03-27

TACTIC

Phase 2 Recruiting

Gastrointestinal

Advanced Biliary Tract Carcinoma

NCT07489976 2026-03-27

IIT2025-03-YANG-LIFT-HCC

Phase 2 Recruiting

Hepato Cellular Carcinoma

NCT05388006 2026-03-25

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03410615 2026-03-24

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03937830 2026-03-24

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05696782 2026-03-23

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06040099 2026-03-19

EMERALD-Y90

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06606847 2026-03-18

LADOGA

Phase 2 Active not recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04301778 2026-03-13

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Phase 2 Completed

5 enrolled 13 charts

Gastrointestinal

Cholangiocarcinoma

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT05845450 2026-03-12

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03753919 2026-03-11

DUTHY

Phase 2 Terminated

79 enrolled 25 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT05061550 2026-03-11

NeoCOAST-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05632809 2026-03-11

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Phase 2 Recruiting

Lung Neoplasms

NCT07459634 2026-03-10

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Phase 2 Not yet recruiting

Small Cell Lung Carcinoma

NCT06859684 2026-03-09

HAIC-quad

Phase 2 Recruiting

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT04705818 2026-03-06

CAIRE

Phase 2 Completed

GastrointestinalSarcoma

Tertiary Lymphoid Structures, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms